Let's look at why this news could be a game-changer for Eli Lilly and its stock.

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

OrderlyMeds fights back after Big Pharma crackdown, igniting a battle over the future of personalized medicine ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Where will Eli Lilly be in five years? Lilly's Mounjaro and Zepbound, which share the same generic drug (tirzepatide), are already giving Ozempic and Wegovy, which also share the same generic ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.